Struggling Ionis licenses Bicycle Therapeutics' platform in a bid to develop drugs that can cross blood-brain barrier
Attempting to rebound from setbacks earlier this year, Ionis has enlisted a new partner in a quest to create drugs that can cross the blood-brain barrier. And the technology comes from a British biotech primarily known for its efforts into oncology.
The collaboration will see Ionis exclusively license a platform from Bicycle Therapeutics to develop oligonucleotides targeting the transferrin receptor 1, the companies announced Tuesday morning. Bicycle is nabbing $45 million upfront and an $11 million equity investment from Ionis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.